Craig B. Thompson, MD, has been named President and CEO of Memorial Sloan-Kettering Cancer Center, succeeding Harold Varmus, MD, who left to become Director of the National Cancer Institute. Since 2006, Dr. Thompson, 57, has served as Director of the Abramson Cancer Center at the University of Pennsylvania and Associate Vice President for Cancer Services in the University of Pennsylvania Health System. He currently serves as Chair of the Howard Hughes Medical Institute Advisory Board and was an HHMI investigator from 1993 to 1999. Dr. Thompson is also a member of the Institute of Medicine and the National Academy of Sciences. His appointment will take effect November 2.
Steven Devine, MD, Director of the Blood and Marrow Transplant Program at Ohio State University Comprehensive Cancer Center Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, has been named Chair of the Cancer and Leukemia Group B (CALGB) Transplant Modality Committee. As Chair, Dr. Devine will lead one of the 12 CALGB modality committees that provide advice to six CALGB disease committees concerning the application of treatments. He will also serve as a focus of discussion on innovative treatments, critically assess progress in the field relevant to the design and implementation of group studies, and perform a substantial quality-assurance role.
Andrew J. Fabiano, MD, has joined Roswell Park Cancer Institute (RPCI) as Clinical Assistant Professor of Neurosurgery and Oncology. Dr. Fabiano comes to RPCI from the University at Buffalo School of Medicine & Biomedical Sciences, where he recently completed his residency. His clinical interests include endoscopic neurosurgery, spinal reconstructive surgery, and gamma knife radiosurgery.
Also at RPCI, Martin C. Mahoney, MD, PhD, Associate Professor in the Departments of Health Behavior and Medicine, has been appointed Vice Chair of the American Cancer Society Primary Care Advisory Committee. Dr. Mahoney, a member of the ACS Board of Advisors, Western New York Region, serves as the society's medical spokesman in western New York and is also principal investigator of the ACS-supported Physician Training Award in Preventive Medicine program, which provides specialized training in cancer prevention and control.
Fox Chase Cancer Center has appointed four new physicians to its team: Suzanne Boyle, MD, and Manjula Sharada Naik, MD, attending physicians for the Hospitalist Program in the Department of Medicine; Kenneth P. Patrick, MD, Director of the Hospitalist Program; and Rohit Walia, MD, staff radiologist in the Department of Diagnostic Imaging.
Georgia Institute of Technology has received a EUREKA—Exceptional, Unconventional Research Enabling Knowledge Acceleration—grant from the NIH to design a new way to treat invasive brain tumors. The researchers, led by Ravi Bellamkonda, PhD, of the Wallace H. Coulter Department of Biomedical Engineering at Georgia Tech and Emory University, plan to develop a system that will excavate brain tumor cells by directing them away from their location in the inner brain to a more external location where they can be removed or killed. The NCI is providing approximately $1 million for the grant.
Ian M. Thompson Jr., MD, Professor and Chair of Urology at the University of Texas Health Science Center at San Antonio and Executive Director of its Cancer Therapy & Research Center, has been elected Chairman of the Early Detection Research Network (EDRN), an initiative of the National Cancer Institute. The EDRN is a collaborative effort overseen by the NCI's Division of Cancer Prevention. Dr. Thompson previously held the position of vice chairman for the EDRN, running its executive committee.
Ralph deVere White, MD, Director of the University of California Davis Cancer Center and Professor of Urology there, has received a four-year, $1.1 million grant from the NCI to investigate molecular pathways involved in the failure of drugs designed for slowing the progression of prostate cancer. The grant will be used to advance earlier research looking at how certain molecules make cancer cells resistant to treatments that work initially by blocking the cancer-promoting action of androgen.
The Keck School of Medicine at the University of Southern California has won $23.5 million in federal funding as part of the ongoing NCI national cancer statistics program. The award continues funding that the USC Department of Preventive Medicine has been receiving since 1992. The data collected by the USC LA Cancer Surveillance Program is added into the NCI's Surveillance, Epidemiology and End Results (SEER) program. This is the fourth cycle of funding won by the department.
The University of Texas MD Anderson Cancer Center has received a $20 million donation from H. Ross Perot for research to advance and design novel targeted therapies. The funds will be equally divided between two new initiatives at the cancer center, an Institute for Personalized Cancer Therapy and a Center for Targeted Therapy.© 2010 Lippincott Williams & Wilkins, Inc.
More on ONCOLOGY-TIMES.com...